fda tirzepatide shortage update π¨ Alert: No Longer on FDA's Drug List As of October 2, 2024, the has announced that the Tirzepatide shortage has been resolved. This means that all doses of FDA Response to Shortage Notification
Description
Clinical trials show average weight loss of 15 to 22% of body weight over 72 weeks, with many patients losing 20 to 25% or more of their starting weight
Lilja, A., Andresen, M., Hadi, A., Christoffersen, D
Higher doses cost more, and the two medications have very different price profiles
if it becomes notable, hold the current dose longer before stepping up
This distinction trips up even experienced users
Commercial and Employer-Sponsored Insurance Plans Whether your patient works for a government entity or a private employer, they will need to check with their specific healthcare plan
